Literature DB >> 29769912

The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases.

J A Bettinger1, S A Halperin2, W Vaudry3, B J Law4, D W Scheifele1.   

Abstract

For almost 25 years the Canadian Immunization Monitoring Program, ACTive (IMPACT) has been conducting active surveillance for severe adverse events following immunization (AEFIs) and vaccine-preventable diseases in children. The network, which consists of volunteer paediatric infectious diseases investigators at 12 tertiary care paediatric hospitals, is an important component of Canada's AEFI monitoring. The network employs nurses at each of the sites to search for and report possible AEFIs to local, provincial and national public health authorities. The active nature of the surveillance ensures a high level of vigilance for severe AEFIs in children.

Entities:  

Year:  2014        PMID: 29769912      PMCID: PMC5868582          DOI: 10.14745/ccdr.v40is3a06

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  10 in total

1.  Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety.

Authors:  David W Scheifele; Scott A Halperin
Journal:  Semin Pediatr Infect Dis       Date:  2003-07

Review 2.  Postvaccination thrombocytopenia in Canada.

Authors:  Laura J Sauvé; Julie Bettinger; David Scheifele; Scott Halperin; Wendy Vaudry; Barbara Law
Journal:  Pediatr Infect Dis J       Date:  2010-06       Impact factor: 2.129

3.  Do childhood vaccines cause thrombocytopenia?

Authors:  Laura J Sauvé; David Scheifele
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

4.  IMPACT after 17 years: Lessons learned about successful networking.

Authors: 
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

5.  Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada.

Authors:  Karina A Top; Cora M Constantinescu; Julie Laflèche; Julie A Bettinger; David W Scheifele; Wendy Vaudry; Scott A Halperin; Barbara J Law
Journal:  Vaccine       Date:  2013-10-05       Impact factor: 3.641

6.  Disseminated bacille Calmette-Guérin infection: three recent Canadian cases. IMPACT. Immunization Monitoring Program, Active.

Authors:  D Scheifele; B Law; T Jadavji
Journal:  Can Commun Dis Rep       Date:  1998-05-01

7.  Hypotonic-hyporesponsive episodes in children hospitalized at 10 Canadian Pediatric Tertiary-Care Centres, 1991-1994.

Authors:  R Gold; D Scheifele; S Halperin; P Déry; B Law; M Lebel; N MacDonald; E Mills; R Morris; T Jadavji; V Marchessault; P Duclos
Journal:  Can Commun Dis Rep       Date:  1997-05-15

8.  Serious adverse events associated with bacille Calmette-Guérin vaccine in Canada.

Authors:  Shelley L Deeks; Michael Clark; David W Scheifele; Barbara J Law; Meenakshi Dawar; Nooshin Ahmadipour; Wikke Walop; C Edward Ellis; Arlene King
Journal:  Pediatr Infect Dis J       Date:  2005-06       Impact factor: 2.129

9.  Thrombocytopenia after immunization of Canadian children, 1992 to 2001.

Authors:  Taj Jadavji; David Scheifele; Scott Halperin
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

10.  Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT.

Authors:  Nicole Le Saux; Nicholas J Barrowman; Dorothy L Moore; Sharon Whiting; David Scheifele; Scott Halperin
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

  10 in total
  5 in total

1.  Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop.

Authors:  A D Cox; L Barreto; M Ulanova; M G Bruce; Rsw Tsang
Journal:  Can Commun Dis Rep       Date:  2017-05-04

2.  Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013-2016.

Authors:  N Ahmadipour; K Watkins; M Fréchette; C Coulby; H Anyoti; K Johnson
Journal:  Can Commun Dis Rep       Date:  2018-09-06

3.  Vaccine vigilance in Canada: Is it as robust as it could be?

Authors:  P Duclos
Journal:  Can Commun Dis Rep       Date:  2014-12-04

4.  Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome.

Authors:  Ling Ling; Sean M Bagshaw; Pierre-Marc Villeneuve
Journal:  CMAJ       Date:  2021-11-22       Impact factor: 8.262

5. 

Authors:  Ling Ling; Sean M Bagshaw; Pierre-Marc Villeneuve
Journal:  CMAJ       Date:  2022-01-24       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.